

USSN 10/068,426

Claim 1 (currently amended): A fusion polypeptide comprising a first polypeptide operably linked to a second polypeptide,

wherein the first polypeptide comprises a polypeptide sequence with at least 85% homology to an extracellular portion at least a region of a glycoprotein Iba polypeptide of SEQ ID NO:1, and said first polypeptide binds a polypeptide selected from the group consisting of leukocyte integrin Mac-1 polypeptide, von Willebrand factor, thrombin and P-selectin; and

wherein the second polypeptide comprises at least a region of an immunoglobulin heavy chain polypeptide.

Claim 2 (cancelled)

Claim 3 (currently amended): The fusion polypeptide of claim 2 1, wherein said first polypeptide binds to ~~one or more~~ at least two of the polypeptides selected from the group consisting of a-leukocyte integrin Mac-1 polypeptide, von Willebrand factor, thrombin and P-selectin.

Claim 4 (cancelled)

Claim 5 (currently amended): The fusion polypeptide of claim 1, wherein said polypeptide comprises SEQ ID NO:4 5.

USSN 10/068,426

Claim 6 (currently amended): The fusion polypeptide of claim 1, wherein said ~~first polypeptide~~ fusion polypeptide is more resistant to proteolysis than a wild-type GPIb $\alpha$  polypeptide.

Claim 7. (original): The fusion polypeptide of claim 1, wherein said first polypeptide binds with higher affinity to a von ~~Willebrand~~ Willebrand factor polypeptide than a wild-type glycoprotein Ib $\alpha$  polypeptide binds to said von ~~Willebrand~~ Willebrand factor polypeptide.

Claim 8 (original): The fusion polypeptide of claim 7 1, wherein said first polypeptide comprises at least one of the amino acid substitutions G233V or M239V relative to the amino acid sequence of a wild-type GPIb $\alpha$  polypeptide.

Claim 9 (currently amended): The fusion polypeptide of claim 7 1, wherein said first polypeptide comprises the amino acid substitutions G233V and M239V relative to the amino acid sequence of a wild-type GPIb $\alpha$  polypeptide.

Claim 10 (cancelled)

Claim 11 (original): The fusion polypeptide of claim ~~10~~ 1, wherein said second polypeptide comprises an Fc region of an immunoglobulin heavy chain.

USSN 10/068,426

Claim 12 (original): The fusion polypeptide of claim 11, wherein said second polypeptide has less effector function than the effector function of a Fc region of a wild-type immunoglobulin heavy chain.

Claim 13 (original): The fusion polypeptide of claim 12, wherein said second polypeptide binds with low or no affinity to a Fc receptor.

Claim 14 (original): The fusion polypeptide of claim 12, wherein said second polypeptide binds with low or no affinity to complement protein C1q.

Claims 15-19 (cancelled)

Claim 20 (currently amended): The fusion polypeptide of claim 1, wherein said fusion polypeptide comprises the amino acid sequence of ~~GP1b302-Ig~~ GpIb $\alpha$ 302 Ig (SEQ ID NO:1), ~~Gp1b302/2A-Ig~~ GpIb $\alpha$ 302/2A-Ig (SEQ ID NO:2), ~~GP1b302/4X-Ig~~ GPIb $\alpha$ 302/4X-Ig (SEQ ID NO:3), ~~GP1b290-Ig~~ GPIb $\alpha$ 290 Ig (SEQ ID NO:4), ~~GP1b290/2V-Ig~~ GPIb $\alpha$ 290/2V-Ig (SEQ ID NO:5.) and or ~~GP1b290/1A-Ig~~ GPIb $\alpha$ 290/1A-Ig (SEQ ID NO:6).

Claim 21 (original): A multimeric polypeptide comprising the fusion polypeptide of claim 1.

USSN 10/068,426

Claim 22 (original): The multimeric polypeptide of claim 21, wherein said multimeric polypeptide is a dimer.

Claims 23-26 (cancelled)

Claim 27 (original): A pharmaceutical composition comprising the fusion polypeptide of claim 1.

Claim 28-53 (cancelled)

Claim 54 (new) The fusion polypeptide of claim 1, wherein said first polypeptide binds at least three polypeptides selected from the group consisting of leukocyte integrin Mac-1 polypeptide, von Willebrand factor, thrombin and P-selectin.

Claim 55 (new) The fusion polypeptide of claim 1, wherein said first polypeptide binds leukocyte integrin Mac-1 polypeptide, von Willebrand factor, thrombin and P-selectin.

Claim 56 (new) The fusion polypeptide of claim 1, wherein said first polypeptide binds leukocyte integrin Mac-1 polypeptide.

Claim 57 (new) The fusion polypeptide of claim 1, wherein said first polypeptide binds von Willebrand factor.

USSN 10/068,426

Claim 58 (new) The fusion polypeptide of claim 1, wherein said first polypeptide binds thrombin.

Claim 59 (new) The fusion polypeptide of claim 1, wherein said first polypeptide binds P-selectin.

Claim 60 (new): A fusion polypeptide comprising a first polypeptide operably linked to a second polypeptide,

wherein the first polypeptide consists essentially of a polypeptide sequence with at least 85% homology to an extracellular portion of a glycoprotein Iba polypeptide of SEQ ID NO:1 and said first polypeptide binds von Willebrand factor polypeptide; and

wherein the second polypeptide consists essentially of an immunoglobulin heavy chain polypeptide, wherein said immunoglobulin heavy chain polypeptide comprises a Fc region.

Claim 61 (new): A polypeptide comprising the amino acid sequence of SEQ ID NO:1.

Claim 62 (new): The polypeptide of claim 61, wherein the amino acid sequence of the polypeptide consists essentially of SEQ ID NO:1.